Dubin C, Del Duca E, Guttman-Yassky E. Ther Clin Risk Manag. 2020;16:1319–1332.
The authors have advised the drug, ARQ-252, was misnamed in the paper as roflumilast
(which is called ARQ-151 and ARQ-154 by the manufacturer). The drug named ARQ-252
by the manufacturer should instead be classified as a JAK1 inhibitor in the paper.
On page 1320, CHE Treatment Paradigm section, 1st paragraph, “There are also ongoing
studies with phosphodiesterase type 4 inhibitors (PDE4) and inhibitors of highly inflammatory
chemokines CCL2 and CCL5 for the treatment of mild to moderate CHE.1,35–38” should
read “There are also ongoing studies with topical JAK1 inhibitors and inhibitors of
highly inflammatory chemokines CCL2 and CCL5 for the treatment of mild to moderate
On page 1322, Table 1, Agent and Target/Mechanism columns, “Roflumilast (ARQ-252)”
should read “ARQ-252” and “PDE4” should read “JAK1”.
On page 1323, before Roflumilast section, new section added for ARQ-252:
Another topical JAK inhibitor is currently under investigation for the treatment of
CHE. ARQ-252, a topical JAK1 inhibitor, is under clinical evaluation in a phase 1/2b
randomized parallel assignment trial involving 223 patients with chronic hand eczema.37,90
On page 1323, Roflumilast section now reads “Roflumilast is a high potency selective
inhibitor of the receptor for PDE4, which functions by degrading cyclic adenosine
monophosphate (cAMP).89 Blocking the PDE-4 receptor allows cAMP to signal the transcription
of immune function genes such as anti-inflammatory IL-10, while simultaneously reducing
the production of inflammatory cytokines such as TNFα and IFN γ, which have been identified
as possibly involved in CHE.15,91-93 Roflumilast has been investigated as a topical
therapeutic for AD,89 and though there are no current trials, it remains a possible
therapeutic option for CHE in the future.
The authors apologize for this error.